Can-Fite BioPharma (CANF) Net Income towards Common Stockholders (2013 - 2023)

Can-Fite BioPharma (CANF) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$28.5 million in Q4 2023.

• Quarterly Net Income towards Common Stockholders fell 2.89% year-over-year to -$28.5 million in Q4 2023, while the trailing twelve-month figure through Jun 2025 was -$28.5 million (up 13.96% YoY) and the FY2025 annual result came in at -$9.8 million, down 24.72% from the prior year.
• Net Income towards Common Stockholders slipped to -$28.5 million in Q4 2023, from -$1.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $14.0 million in Q2 2020 to a low of -$28.5 million in Q4 2023.
• A 5-year average of -$6.1 million and a median of -$2.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2019 — Net Income towards Common Stockholders soared 1565.54% — and 2020, when it slumped 794.54%.
• Tracing CANF's Net Income towards Common Stockholders over 5 years: stood at -$20.5 million in 2019, then jumped by 78.76% to -$4.3 million in 2020, then tumbled by 54.28% to -$6.7 million in 2021, then sank by 312.87% to -$27.7 million in 2022, then fell by 2.89% to -$28.5 million in 2023.
• The last three Net Income towards Common Stockholders figures came in at -$28.5 million (Q4 2023), -$1.9 million (Q3 2023), and -$2.8 million (Q2 2023), per Business Quant data.